EXHIBIT B
SCHEDULE OF PURCHASERS
Exhibit B to the Note Purchase Agreement, dated September 12, 2025, by and among Genome Dx Therapeutics Inc. and the Purchasers listed herein.
The following sets forth the name, address for notices, principal amount of the Convertible Promissory Note (the "Note"), and entity classification for each Purchaser (each, a "Purchaser" and collectively, the "Purchasers") under that certain Note Purchase Agreement, dated as of September 12, 2025 (the "Note Purchase Agreement"), by and among Genome Dx Therapeutics Inc., a Delaware corporation (the "Company"), and the Purchasers identified below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Note Purchase Agreement. The address set forth opposite each Purchaser's name below shall constitute such Purchaser's address for all notices and other communications delivered pursuant to Section 9.1 of the Note Purchase Agreement, unless such Purchaser provides written notice of a change of address in accordance therewith.
The Total Aggregate Principal Amount of the Notes to be issued to all Purchasers listed above is Eight Million Dollars ($8,000,000), representing the sum of $1,500,000 + $500,000 + $1,000,000 + $5,000,000 = $8,000,000.
Each Purchaser listed above has represented and warranted to the Company that such Purchaser is an "accredited investor" as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and has executed and delivered to the Company an Accredited Investor Questionnaire in the form attached as Exhibit D to the Note Purchase Agreement.
This Schedule of Purchasers is an integral part of, and is incorporated by reference into, the Note Purchase Agreement dated September 12, 2025. In the event of any conflict between this Schedule and the Note Purchase Agreement, the terms of the Note Purchase Agreement shall govern.
| Purchaser Name | Address for Notices | Principal Amount of Note | Entity Type / Accredited Investor Status |
| Dr. Lena Vasquez | 2288 La Jolla Scenic Drive, La Jolla, CA 92037 | $1,500,000 | Individual — Accredited Investor |
| Dr. Franklin Osei | 815 Prospect Street, Unit 4A, La Jolla, CA 92037 | $500,000 | Individual — Accredited Investor |
| James Calloway | 390 Park Avenue, 18th Floor, New York, NY 10022 | $1,000,000 | Individual — Accredited Investor |
| Stonebridge Capital Partners Fund III, L.P. | 390 Park Avenue, 18th Floor, New York, NY 10022 | $5,000,000 | Limited Partnership — Accredited Investor |
| Total Aggregate Principal Amount | $8,000,000 |
EXHIBIT B
SCHEDULE OF PURCHASERS
Exhibit B to the Note Purchase Agreement, dated September 12, 2025, by and among Genome Dx Therapeutics Inc. and the Purchasers listed herein.
The following sets forth the name, address for notices, principal amount of the Convertible Promissory Note (the "Note"), and entity classification for each Purchaser (each, a "Purchaser" and collectively, the "Purchasers") under that certain Note Purchase Agreement, dated as of September 12, 2025 (the "Note Purchase Agreement"), by and among Genome Dx Therapeutics Inc., a Delaware corporation (the "Company"), and the Purchasers identified below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Note Purchase Agreement. The address set forth opposite each Purchaser's name below shall constitute such Purchaser's address for all notices and other communications delivered pursuant to Section 9.1 of the Note Purchase Agreement, unless such Purchaser provides written notice of a change of address in accordance therewith.
The Total Aggregate Principal Amount of the Notes to be issued to all Purchasers listed above is Eight Million Dollars ($8,000,000), representing the sum of $1,500,000 + $500,000 + $1,000,000 + $5,000,000 = $8,000,000.
Each Purchaser listed above has represented and warranted to the Company that such Purchaser is an "accredited investor" as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and has executed and delivered to the Company an Accredited Investor Questionnaire in the form attached as Exhibit D to the Note Purchase Agreement.
This Schedule of Purchasers is an integral part of, and is incorporated by reference into, the Note Purchase Agreement dated September 12, 2025. In the event of any conflict between this Schedule and the Note Purchase Agreement, the terms of the Note Purchase Agreement shall govern.
Purchaser Name | Address for Notices | Principal Amount of Note | Entity Type / Accredited Investor Status
Dr. Lena Vasquez | 2288 La Jolla Scenic Drive, La Jolla, CA 92037 | $1,500,000 | Individual — Accredited Investor
Dr. Franklin Osei | 815 Prospect Street, Unit 4A, La Jolla, CA 92037 | $500,000 | Individual — Accredited Investor
James Calloway | 390 Park Avenue, 18th Floor, New York, NY 10022 | $1,000,000 | Individual — Accredited Investor
Stonebridge Capital Partners Fund III, L.P. | 390 Park Avenue, 18th Floor, New York, NY 10022 | $5,000,000 | Limited Partnership — Accredited Investor
Total Aggregate Principal Amount | $8,000,000